Lipid lowering therapy in the elderly: Is there a benefit?

Current Pharmaceutical Design

Volumn 12, Issue 30, 2006, Pages 3945-3960

  Kalantzi, Kallirroi J ^a   Milionis, Haralampos J ^a   Mikhailidis, Dimitri P ^b   Goudevenos, John A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Cholesterol lowering; Elderly; Lipids; Prevention; Statins

Indexed keywords

ANDROGEN; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOFIBRATE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CORTICOSTEROID DERIVATIVE; ESTROGEN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; RECOMBINANT GROWTH HORMONE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG;

AGE; AGED; ALZHEIMER DISEASE; ATHEROSCLEROSIS; BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL STUDY; CLINICAL TRIAL; COMORBIDITY; COST OF ILLNESS; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG COST; DYSLIPIDEMIA; ECONOMIC EVALUATION; ELDERLY CARE; ERECTILE DYSFUNCTION; FINANCIAL MANAGEMENT; GERIATRIC PATIENT; HEALTH CARE COST; HEALTH STATUS; HEALTH SURVEY; HEART MUSCLE ISCHEMIA; HORMONE DEFICIENCY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTHYROIDISM; KIDNEY DYSFUNCTION; LIFESTYLE; LIVER DYSFUNCTION; LIVER TOXICITY; MEDICAL DECISION MAKING; METABOLIC SYNDROME X; MUSCLE WEAKNESS; MYOPATHY; OBESITY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REVIEW; SOCIAL PSYCHOLOGY;

AGE FACTORS; AGED; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS;

EID: 33749856621     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778559669     Document Type: Review

References (198)

1. Lye M, Donellan C. Heart disease in the elderly. Heart 2000; 84: 560-66.
2. US Bureau of the census: sixty five plus in America.
3. Wei JY, Gersh BJ. Heart disease in the elderly. Curr Probl Cardiol 1987; 12: 1-65.
4. Chrischilles EA, Foley DJ, Wallace RB, Lemke JH, Semla TP, Hanlon JT, et al. Use of medications by persons 65 and over: data from the established populations for epidemiologic studies of the elderly. J Gerontol 1992; 47: M137-44.
5. American Heart Association 2000 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association 1999.
6. Shepherd J. Issues surrounding age: vascular disease in the elderly. Curr Opin Lipidol 2001; 12: 601-9.
7. Stone PH, Thompson, B, Anderson HV, Kronenberg MV, Gibson RS, Rogers WJ, et al. Influence of race, sex and age on the management of unstable angina and non Q-wave myocardial infarction. The TIMI III registry. JAMA 1996; 275: 1104-12.
8. Williams MA, Fleg JL, Ades PA, Chaitman BR, Miller NH, Mohiuddin SM, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients 75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002; 105: 1735-43.
9. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes. A 26 year follow up of the Framingham population. Am Heart J 1986; 111: 383-90.
10. Aronow WS, Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol 1996; 77: 864-6.
11. Bonita R. Epidemiology of stroke. Lancet 1992; 339: 342-4.
12. Futterman LG, Lemberg L. Stroke risk, cholesterol and statins. Am J Crit Care 1999; 8: 416-9.
13. Milionis HJ, Liberopoulos E, Goudevenos J, Bairaktari ET, Seferiadis K, Elisaf MS. Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. Int J Cardiol 2005; 99: 269-75.
14. Milionis HJ, Rizos E, Goudevenos J, Seferiadis K, Mikhailidis DP, Elisaf MS. Components of the Metabolic Syndrome and Risk for First-Ever Acute Ischemic Nonembolic Stroke in Elderly Subjects. Stroke 2005; 36: 1372-6.
15. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71: 510-5.
16. Hiatt WR, Marshall JA, Baxter J, Sandoval R, Hildebrandt W, Kahn LR, et al. Diagnostic methods for peripheral arterial disease in the San Luis Valley Diabetes Study. J Clin Epidemiol 1990; 43: 597-606.
17. Schroll M, Munck O. Estimation of peripheral arteriosclerotic disease by ankle blood pressure measurements in a population study of 60-year-old men and women. J Chron Dis 1981; 34: 261-9.
18. Daskalopoulou SS, Daskalopoulos ME, Liapis CD, Mikhailidis DP. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem 2005; 12: 443-52.
19. Tuomilehto J. Impact of age on cardiovascular risk: implications for cardiovascular disease management. Atherosclerosis Supplements 2004; 5: 9-17.
20. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins and the risk of coronary heart disease. The Framingham Study. Ann Intern Med 1971; 74: 1-12.
21. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/ Texas Coronary Atherosclerosis Prevention Study. JAMA 1998: 279; 1615-22.
22. Cholesterol, diastolic blood pressure and stroke: 13,000 strokes in 450, 000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 1995; 346: 1647-53.
23. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Mac Farlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
24. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
25. Pfeffer MA, Sacks FM, Moye LA, Brown L, Rouleau JL, Hartley LH, et al. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol 1995; 76: 98C-106C.
26. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-57.
27. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diab Care 2001; 24: 683-9.
28. Martin MJ, Holley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361, 662 men. Lancet 1986; 2: 933-6.
29. Krumholz HM, Seeman TE, Merrill SS, Mendes de Leon CF, Vaccarino V, Silverman DI, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994; 272: 1335-40.
30. Kronmal R, Cain K, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age: a report based on the Framingham data. Arch Intern Med 1993; 153: 1065-73.
31. Forette B, Tortrat D, Wolmark Y. Cholesterol as risk factor for mortality in elderly women. Lancet 1989; 1: 868-70.
32. Casiglia E, Mazza A, Tikhonoff V, Scarpa R, Schiavon L, Pessina AC. Total cholesterol and mortality in the elderly. J Intern Med 2003; 254: 353-62.
33. Kreisberg RA, Kasim, S. Cholesterol metabolism and aging. Am J Med 1987; 82: 54-60.
34. Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Circulation 1997; 96: 37-43.
35. Hazzard WR, Ettinger WH. Aging and atherosclerosis: changing considerations in cardiovascular disease prevention as the barrier to immortality is approached in old age. Am J Geriatr Cardiol 1995; 4: 16-36.
36. Noel M, Smith T, Ettinger W. Characteristics and outcomes of hospitalized older patients who developed hypocholesterolemia. J Am Geriatric Soc 1991; 39: 455-61.
37. Ettinger W, Harris T. Causes of hypocholesterolemia. Coron Artery Dis 1993; 4: 854-9.
38. Corti MC, Guralnik JM, Salive ME, Harris T, Field TS, Wallace RB, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 1995; 274: 539-44.
39. Barrett-Connor E, Suarez L, Khaw K, Criqui MH, Wingard DL. Ischemic heart disease risk factors after age 50. J Chronic Dis 1984; 37: 903-8.
40. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA 1986; 256: 2835-8.
41. Benefante R, Reed W. Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? JAMA 1990; 263: 393-6.
42. Leupker RV. Dyslipoproteinemia in the elderly. Endocrinol Metab Clin North Am 1990; 19: 451-63.
43. Frost PH, Davis BR, Burlando AJ, Curb JD, Guthrie GP, Isaacsohn JL, et al. Serum lipids and incidence of coronary heart disease. Circulation 1996; 94: 2381-8.
44. Houterman S, Verschuren WM, Hofman A, Witterman JC. Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: the Rotterdam Study. J Intern Med 1999; 246: 25-33.
45. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp, RG. Total cholesterol and risk of mortality in the oldest old. Lancet 1997; 350: 1119-23.
46. Pekkanen J, Nisssinen A, Vartiainen E, Salonen JT, Punsar S, Karvonen MJ. Changes in serum cholesterol level and mortality: a 30-year follow-up. Am J Epidemiol 1994; 139: 155-6.
47. Goldstein JL, Brown MS. Lipoprotein receptors, cholesterol metabolism, and atherosclerosis. Arch Pathol 1975; 99: 181-4.
48. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002; 8; 1257-62.
49. Ericsson S, Eriksson M, Vitols S, Einarsson K, Berglun L, Angelin B. Influence of age on the metabolism of plasma low density lipoproteins in healthy males. J Clin Invest 1991; 87: 591-6.
50. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease, The Framingham Study. Am J Med 1977; 62: 707-4.
51. Jousilahti P, Vartiainen E, Tuomilehto J, Pekkanen J, Pushka P. Role of known risk factors in explaining the difference in the risk of coronary heart disease between eastern and southern Finland. Ann Med 1998; 30: 481-7.
52. Shepherd J, Blauw GL, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. PROSPER study group. PROspective Study of Pravastatin in Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30.
53. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 11: 2-14.
54. Aronow WS, Herzig AH, Etienne F, D'Alba P, Ronquillo J. 41-month follow-up of risk factors correlated with new coronary events in 708 elderly patients. J Am Geriatr Soc 1989; 37: 501-6.
55. Walldious G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
56. Bots ML, Witteman JC, Hofman A, de Jong PT, Grobbee DE. Low diastolic blood pressure and atherosclerosis in elderly subjects. The Rotterdam Study. Arch Intern Med 1996; 156: 843-8.
57. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
58. Villareal DT, Apovian CM, Kushner RG, Klein S. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr 2005; 82: 923-34.
59. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998; 22: 39-47.
60. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195-200.
61. Wallace JI, Schwartz RS. Involuntary weight loss in elderly outpatients: recognition, etiologies, and treatment. Clin Geriatr Med 1997; 13: 717-35.
62. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288: 1723-7.
63. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-43.
64. Kennedy RL, Chokkalingham K, Srinivasan R. Obesity in the elderly: who should we be treating, and why, and how? Curr Opin Clin Nutr Metab Care 2004; 7: 3-9.
65. Dewan S, Wilding JP. Obesity and type-2 diabetes in the elderly. Gerontology 2003; 49: 137-45.
66. Frost PH, Davis BR, Burlando AJ, Curb JD, Guthrie JP, Isaacsohn JL, et al. for the Systolic Hypertension in the Elderly Research Group. Coronary heart disease risk factors in men and women aged 60 years and older findings from the Systolic Hypertension in the Elderly Program. Circulation 1996; 94: 26-34.
67. Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish studies. Ann Intern Med 1996; 124: 127-30.
68. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
69. Ezenwaka CE, Offiah NV. Differences in cardiovascular disease risk factors in elderly and younger patients with type 2 diabetes in the West Indies. Singapore Med J 2002; 43: 497-503.
70. DECODE Study Group, European Diabetes Epidemiology Group.Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26: 688-96.
71. Glucose tolerant and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative Analysis of Diagnostic criteria in Europe. Lancet 1999; 354: 617-21.
72. Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study. Diabetes Epidemiology: Collaborative Analysis of Diagnostic criteria in Europe. Diab Care 1999; 22: 1667-71.
73. Balkau B. The DECODE Study. Diabetes Epidemiology: Collaborative Analysis of Diagnostic criteria in Europe. Dish Metab 2000; 26: 282-6.
74. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893-8.
75. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163:427-36.
76. Goodpaster BH, Krishnaswami S, Harris TB, Katsiavas A, Kritchevsky SP, Simonsick EM, et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med 2005; 165: 777-83.
77. Athyros VG, Bouloukos VI, Pehlivanidis AN, Papageorgiou AA, Dionysopoulou SG, Symeonidis AN et al, MetS-Greece Collaborative Group. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab 2005; 7: 397-405.
78. Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Ganotakis ES, Symeonidis AN, et al. METS-GREECE Collaborative Group. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin 2004; 20: 1691-701.
79. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999; 99: 2192-217.
80. Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky L. The Epidemiology, Pathophysiology, and Management of Psychosocial Risk Factors in Cardiac Practice. J Am Coll Cardiol 2005; 45: 637-51.
81. Bostom AG, Sibershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999; 159: 1077-80.
82. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hoffman A, Witteman JC, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: The Rotterdam study. Arch Intern Med 1999; 159: 38-44.
83. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506-12.
84. Volpato S, Guralnik JM, Ferrucci L, Belfour J, Chaves P, Fried LP, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women: The Women's Health and Aging Study. Circulation 2001; 103: 947-53.
85. Kaplan RC, Heckbert SR, Furberg CD, Psaty BM. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol 2002; 55: 654-64.
86. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084-91.
87. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988; 33: 667-72.
88. Harris KPG, Pukerson ML, Yates J, Klahr S. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephritic syndrome. Am J Kidney Dis 1990; 15: 16-23.
89. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
90. Athyros VG, Mikhailidis DP, Papageorgiou A, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-34.
91. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. for the GREACE Study Collaborative Group. Effect of Statins Versus Untreated Dyslipidemia on Serum Uric Acid Levels in Patients With Coronary Heart Disease: A Subgroup Analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study Am J Kidney Dis 2004; 43: 589-99.
92. Manttari M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 1995; 26: 670-675.
93. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83-90.
94. Sullivan ME, Keoghane SR, Miller MA. Vascular risk factors and erectile dysfunction. BJU Int 2001; 87: 838-45.
95. Kloner RA, Speakman M. Erectile dysfunction and atherosclerosis. Curr atheroscler Rep 2002; 4: 397-401.
96. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
97. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985; 1: 181-4.
98. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study (with discussion). J Urol 2001; 166: 569-75.
99. Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A, Thomas S, et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community based study. J Am Geriatr Soc 2001; 49: 436-42.
100. Levine LA, Kloner RA. Importance of asking questions about erectile dysfunction. Am J Cardiol 2000; 86: 1210-3.
101. Nehra A, Kulaksizoglu H. Global perspectives and controversies in the epidemiology of male erectile dysfunction. Curr Opin Urol 2002; 12: 493-6.
102. Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 1997; 9: 123-6.
103. Solomon H, Man JW, Wierzbicki AS, Jackson G. Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol 2003; 91: 230-1.
104. Fung MM, Bettencourt R, Barrett-Connor E. Heart Disease Risk Factors Predict Erectile Dysfunction 25 Years Later, The Rancho Bernardo Study. J Am Coll Cardiol 2004; 43: 1405-11.
105. Harman SM, Blackman MR. Use of growth hormone for prevention or treatment of effects of aging. J Gerontol A Biol Sci Med Sci 2004; 59: 652-8.
106. Schleich F, Legros JJ. Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male. Eur J Endocrinol 2004; 151: 415-24.
107. Grundy SM. The role of cholesterol management in coronary disease risk reduction in elderly patients. Endocrinol Metab Clin North Am 1998; 27: 655-75.
108. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. JAMA 1998; 280: 605-13.
109. Herrington DM, Reboussin DM, Brosnihan KB, Shazp PC, Skuwarkez SA, Suydez TA, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522-9.
110. Barrett-Connor E, Laughlin GA. Hormone therapy and coronary artery calcification in asymptomatic postmenopausal women: the Rancho Bernardo Study. Menopause 2005; 12: 40-8.
111. Ansell BJ, Watson KE, Fogelman AM. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program. JAMA 1999; 282: 2051-7.
112. Deedwania P. Hypercholesterolemia. Is lipid-lowering worthwhile for elderly patients? Geriatrics 2000; 55: 22-8.
113. Lemaitre RN, Psaty BM, Heckbert SR, Kronmal RA, Newman AB, Burke GL. Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the cardiovascular health study. Arch Intern Med 2002; 162: 1395-400.
114. Colhoun HM, Betteridge DJ, Durrington PN, Hitman Ga, Neil HAW, Livingstone SJ, et al. on behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 2004; 364: 685-96.
115. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet 2003; 361: 1149-58.
116. Carlson LA, Rosenhamer G. Reduction of morality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405-18.
117. LaRosa JC, Applegate W, Crouse JR, Hunninghake DB, Grimm R, Knopp R, et al. Cholesterol lowering in the elderly. Results of the cholesterol reduction in seniors program (CRISP) pilot study. Arch Intern Med 1994; 154: 529-39.
118. LaRosa JC. Dyslipidemia and coronary artery disease in the elderly. Clin Geriatr Med 1996; 12: 33-40.
119. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-89.
120. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
121. Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, et al. for the CARE Investigators. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Ann Intern Med 1998; 129: 681-9.
122. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
123. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Education Program goal versus "usual" care in secondary coronary heart disease prevention. The Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220-8.
124. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Myocardial Ischemia reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8.
125. Bruckert E, Lievre M, Giral P, Crepaldi G, Masana L, Vrolix M, et al. Efficacy and safety of fluvastatin XL in a large cohort of elderly patients. Am J Geriatr Cardiol 2003; 12: 225-31.
126. Serruys PW, De Feyter P, Macaya C, Kokott N, Puel J, Vrolix M. Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287: 3215-22.
127. Koren MJ, Hunninghake DB, on behalf of the ALLIANCE Investigators Clinical Outcomes in Managed-Care Patients With Coronary Heart Disease Treated Aggressively in Lipid-lowering Disease Management Clinics The ALLIANCE Study J Am Coll Cardiol 2004; 44: 1772-9.
128. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, et al. for the Treating to New Targets (TNT) Investigators. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N Engl J Med 2005; 352: 1425-35.
129. Amarenco P, Bogousslavsky J, Callahan AS, Goldstein L, Hennerici M, Sillsen H, et al. SPARCL Investigators. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc. Dis 2003; 16: 389-95.
130. Deedwania PC; Study Assessing Goals in the Elderly steering committee and investigators. Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE). Am Heart J 2004; 148: 1053-9.
131. Davidson MH, Kurlandsky SB, Kleinpell RM, Maki KC. Lipid management and the elderly. Prev Cardiol 2003; 6: 128-33; 134-5.
132. Papadakis JA, Milionis HJ, Press M, Mikhailidis DP. Treating dyslipidaemia in non-insulin dependent diabetes mellitus - a special reference to statins. J Diabetes Complic 2001; 15: 211-26.
133. Hazzard R. Dyslipoproteinemia in the Elderly: To treat or not to treat? Am J Med 1999; 107: 51-3.
134. Santanello NC, Barber BL, Applegate WB, Elam J, Curtis C, Hunninghake DB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction In Seniors Program (CRISP) pilot study. J Am Geriatr Soc 1997; 45: 8-14.
135. Gaw A. The care gap: underuse of statin therapy in the elderly Int J Clin Pract 2004; 58: 777-85.
136. Evans M, Rees A. Effects of HMG-Co reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25: 649-63.
137. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/ NHLBI clinical advisory on the use and safety of statins. Circulation 2002; 106: 1024-8.
138. Rosenson RS. Statins and the risk of rhabdomyolysis. J Endocrinol Invest 2002; 25: 577.
139. Rosenson RS. Current Overview of Statin-Induced Myopathy. Am J Med 2004; 116: 408-16.
140. Sica DA, Gehr TW. Rhabdomyolysis and statin therapy: relevance to the elderly. Am J Geriatr Cardiol 2002; 11: 48-55.
141. l Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25: 649-63.
142. Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001; 175: 486-9.
143. Grundy SM, Cleeman JI, Rifkind BM, Kuller LH. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med 1999; 159: 1670-8.
144. Miettinen TA, Pyorala K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, et al. for the Scandinavian Simvastatin Study Group. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96: 4211-8.
145. Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 2001; 134: 931-40.
146. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
147. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999; 100: 1481-92.
148. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation and Treatment of High blood Cholesterol (Adult Treatment Panel II). Circulation 1994; 89: 1329-445.
149. Denke MA, Grundy SM. Hypercholesterolemia in elderly persons: resolving the treatment dilemma. Ann Intern Med 1990; 112: 780-92.
150. Milionis HJ, Rizos E, Mikhailidis DP. Smoking diminishes the beneficial effect. of statins: observations from the landmark trials. Angiology 2001; 52: 575-87.
151. Corr LA, Oliver MF. The low fat/low cholesterol diet is ineffective. Eur Heart J 1997; 18: 18-22.
152. Neil HA, Roe L, Godlee JW, Moore JW, Clark GMG, Brown J, et al. Randomized trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ 1995; 310: 569-73.
153. Holme I. Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomized trials: use of meta-analysis. Br Heart J 1993; 69(Suppl): S42-50.
154. Knapp HR. Dietary fatty acids in human thrombosis and haemostasis. Am J Clin Nutr 1997; 65: S1687-98.
155. Milionis HJ, Elisaf MS, Mikhailidis DP. The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Des 2003; 9: 2425-43.
156. Wierzbicki AS. Lipid-lowering: another method of reducing blood pressure? J Hum Hypertens 2002; 16: 753-60.
157. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-4.
158. Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P, et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000; 30: 980-7.
159. Ikeda T, Sakurai J, Nakayama D, Takahashi Y, Matsuo K, Shibuya Y, et al. Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am J Hypertens 2004; 17: 502-6.
160. Whitney C, Warburton DE, Frohlich J, Chan SY, McKay H, Khan K. Are cardiovascular disease and osteoporosis directly linked? Sports Med 2004; 34: 779-807.
161. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch-Neurol 2000; 57: 1439-43.
162. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356(9242): 1627-31.
163. Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 1996; 16: 921-32.
164. Crisby M, Carlson LA, Winblad B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2002; 16: 131-6.
165. Reiss AB, Siller KA, Rahman MM, Chan ESL, Ghiso J, de Leon MJ. Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease. Neurobiol Aging 2004; 25: 977-89.
166. Scott LJ, Curran MP, Figgitt DP. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs 2004; 4: 117-38.
167. Milionis HJ, Gazi IF, Filippatos TD, Tzovaras V, Chasiotis G, Goudevenos J, et al. Starting with rosuvastatin in primary hyperlipidaemia - Is there more than lipid lowering? Angiology 2005; 56: 585-92.
168. Shepherd J, Hunninghake DB, Stein EA, Kastelein JJ, Harris S, Pears J, et al. Safety of rosuvastatin. Am J Cardiol 2004; 94: 882-8.
169. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The Safety of Rosuvastatin as Used in Common Clinical Practice. A Postmarketing Analysis. Circulation 2005; 111: 3051-7.
170. Lipka L, Sager P, Strony J, Yang B, Suresh R, Veltri E; Ezetimibe Study Group.Efficacy and safety of coadmonistration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drug Aging 2004; 21: 1025-32.
171. Lemaitre RN, Furberg CD, Newman AB, Hulley SB, Gordon DJ, Gottdiener JS, et al. Time trends in the use of cholesterol-lowering agents in older adults. Arch Intern Med 1998; 158: 1761-8.
172. Danias PG, O'Mahonet S, Raddford MJ, Korman L, Silverman DI. Serum cholesterol levels are underevaluated and undertreated. Am J Cardiol 1998; 81: 1353-6.
173. Aronow WS. Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol >125 mg/dL. Am J Cardiol 1998; 82: 668-9.
174. Mendelson G, Aronow WS. Underulization of measurement of serum low-density lipoprotein cholesterol levels and of lipid-lowering therapy in older patients with manifest atherosclerotic disease. J Am Geriatr Soc 1998; 46: 1128-31.
175. Rich SE, Shah J, Rich DS, Shah R, Rich MW. Effects of age, sex, race, diagnosis-related group, and hospital setting on lipid management in patients with coronary artery disease. Am J Cardiol 2000; 86: 328-30.
176. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291: 1864-70.
177. Cherry DK, Burt CW, Woodwell DA. National Ambulatory Medical Care Survey: 1999 Summary. Hyattsville, Md; National Center for Health Statistics; 2001. Advance Data From Vital and Health Statistics, No. 322.
178. Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2000 Summary. Hyattsville, Md; National Center for Health Statistics; 2002. Advance Data From Vital and Health Statistics; No. 328.
179. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
180. Masoudi FA, Krumholz HM. Polypharmacy and comorbidity in heart failure. BMJ 2003; 327: 513-4.
181. Lange RA, Hillis LD. Antiplatelet therapy for ischemic heart disease. N Engl J Med 2004; 350: 277-80.
182. Garber AJ. Benefits of combination therapy of insulin and oral hypoglycemic agents. Arch Intern Med 2003; 163: 1781-2.
183. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-24.
184. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone Survey. JAMA 2002; 287: 337-44.
185. Field TS, Gurwitz JH, Avorn J, McCormick D, Jain S, Eckler M, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001; 161: 1629-34.
186. Sloane PD, Zimmerman S, Brown LC, Ives TJ, Walsh JF. Inappropriate medication prescribing in residential care/assisted living facilities. J Am Geriatr Soc 2002; 50: 1001-11.
187. Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging 2004; 21: 793-811.
188. Federman AD, Adams AS, Ross-Degnan D, Soumerai SB, Ayanian JZ. Supplemental insurance and use of effective cardiovascular drugs among elderly Medicare beneficiaries with coronary heart disease. JAMA 2001; 286: 1732-9.
189. Steinman MA, Sands LP, Covinsky KE. Self-restriction of medications due to costs in seniors without prescription coverage. J Gen Intern Med 2001; 16: 793-9.
190. Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001; 285: 421-9.
191. Gurwitz JH. Polypharmacy: a new paradigm for quality drug therapy in the elderly? Arch Intern Med 2004 11; 164: 1957-9.
192. American Heart Association 2000 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 1999.
193. Sempos CT, Cleeman JI, Carroll MD, Johnson CL, Bachorik PS, Gordon DJ, et al. Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA 1993; 269: 3009-14.
194. Haapanen-Niemi N, Vuori I, Pasanen M. Public health burden of coronary heart disease risk factors among middle-aged and elderly men. Prev Med 1999; 28: 343-8.
195. Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-mediylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999; 159: 593-600.
196. Botham KM, Bravo E, Elliott J, Wheeler-Jones CP. Direct interaction of dietary lipids carried in chylomicron remnants with cells of the artery wall: implications for atherosclerosis development. Curr Pharm Des 2005; 11(28): 3681-95.
197. Milionis HJ, Daskalopoulou SS, Elisaf M, Mikhailidis DP. The predictive value of lipid markers in vascular disease. Curr Pharm Des 2005; 11(17): 2209-24.
198. Napoli C, Sica V. Statin treatment and the natural history of atherosclerotic-related diseases: pathogenic mechanisms and the risk-benefit profile. Curr Pharm Des 2004; 10(4): 425-32.